ArticleScientific reports2015
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Defective biological networks associated with pseudogene-derived lncRNAs in cancer drug resistance: Promising prospects for their clinical targets in cancer therapy.Genes & diseases · 2026Review
- Collision Tumors Involving Metastatic Carcinoma and Plasma Cell Myeloma: Report of Two Cases.Case reports in pathology · 2026Article
- [Progress in metabolomics of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Potential Effect of Extracellular Vesicles in Clinical Settings of Lymphoma.Indian journal of clinical biochemistry : IJCB · 2025Review
- Article
- Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes.International journal of molecular sciences · 2023Article
- Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome.Journal of personalized medicine · 2023Article
- ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma.Onco · 2022Article
- Simultaneous multiple myeloma and non-small cell lung carcinoma: A case report and review of the literature.Oncology letters · 2022Article
- ALCAM regulates multiple myeloma chemoresistant side population.Cell death & disease · 2022Article
- Article
- Proteomics-inspired precision medicine for treating and understanding multiple myeloma.Expert review of precision medicine and drug development · 2020Article
- Diagnostic and Therapeutic Potential of Extracellular Vesicles in B-Cell Malignancies.Frontiers in oncology · 2020Review
- Pathway-structured predictive modeling for multi-level drug response in multiple myeloma.Bioinformatics (Oxford, England) · 2018Article
- Metabolic Features of Multiple Myeloma.International journal of molecular sciences · 2018Review
- The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.Molecular cancer · 2018Review
- Article
- Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles.Scientific reports · 2017Article
- Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS.PloS one · 2017Article
- Cell intrinsic and extrinsic regulation of leukemia cell metabolism.International journal of hematology · 2016Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) was characterized by frequent mutations in KRAS/NRAS/BRAF within the EGFR pathway that could induce resistance to EGFR inhibitors. We here report that EGFR inhibition solely exhibited moderate inhibition in KRAS/NRAS/BRAF wildtype (triple-WT) MM cells, whilst had no effect in myeloma cells with any of the mutated genes. The moderate inhibitory effect was conferred by induction of pentose phosphate pathway (PPP) when cells were treated with Gefitinib, the EGFR inhibitor. Combination of Gefitinib with PPP inhibitor 6AN effected synergistically in triple-WT cells. The inhibition could be restored by addition of NADPH. Dual EGFR/ERBB2 inhibitor Afatinib also exhibited similar effects. Further genetic silencing of EGFR, ERBB2 and mTOR indicated that major effect conferred by ERBB2 was via convergence to EGFR pathway in MM. Our results contributed to the individualized targeted therapy with EGFR inhibitors in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.